News coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended positive on Monday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 47.3303467131954 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Global Type I Hyperlipoproteinemia Drug Market Outlook 2018- Aegerion Pharmaceuticals, Inc., Catabasis … (industrydailynews.com)
- Masimo (MASI) Analysts See $0.70 EPS; 4 Analysts Are Bullish Catabasis Pharmaceuticals, Inc. (CATB) Last Week (mtastar.com)
- How much this stock is Risky? Catabasis Pharmaceuticals, Inc. (CATB) (nasdaqfortune.com)
- Watch-list Stock of Traders: Catabasis Pharmaceuticals, Inc. (CATB) stock price is at $1.86 on volume of 0 shares with … (nasdaqexpress.com)
Shares of CATB stock opened at $1.81 on Monday. The company has a market cap of $52.55, a PE ratio of -1.44 and a beta of 0.80. Catabasis Pharmaceuticals has a 12 month low of $1.09 and a 12 month high of $3.78.
CATB has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Friday, January 5th. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Friday, December 15th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $5.18.
WARNING: “Positive News Coverage Somewhat Unlikely to Impact Catabasis Pharmaceuticals (NASDAQ:CATB) Stock Price” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/2018/04/02/catabasis-pharmaceuticals-catb-getting-favorable-press-coverage-report-shows/2002448.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.